Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP.

J Clin Oncol. 2012 May 1;30(13):1541-9. doi: 10.1200/JCO.2011.39.6671. Epub 2012 Mar 12. Review.

2.

Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND.

Lung. 2014 Feb;192(1):197-203. doi: 10.1007/s00408-013-9526-9. Epub 2013 Oct 30.

PMID:
24170217
3.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
4.

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.

Ak G, Tada Y, Shimada H, Metintas S, Ito M, Hiroshima K, Tagawa M, Metintas M.

BMC Cancer. 2017 Mar 23;17(1):212. doi: 10.1186/s12885-017-3209-5.

5.

Sensitivity of urinary mesothelin in patients with malignant mesothelioma.

Creaney J, Musk AW, Robinson BW.

J Thorac Oncol. 2010 Sep;5(9):1461-6.

6.

Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.

Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.

J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

7.

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Sato T, Suzuki Y, Mori T, Maeda M, Abe M, Hino O, Takahashi K.

Cancer Med. 2014 Oct;3(5):1377-84. doi: 10.1002/cam4.297. Epub 2014 Jul 10.

8.

Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.

Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2014 Dec;34(12):7425-9.

PMID:
25503183
9.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
10.

Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.

Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M.

Eur J Surg Oncol. 2018 Jun;44(6):792-798. doi: 10.1016/j.ejso.2018.02.010. Epub 2018 Feb 17.

PMID:
29503128
11.

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.

Jakubec P, Pelclova D, Smolkova P, Kolek V, Nakladalova M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):472-9. doi: 10.5507/bp.2014.015. Epub 2014 Apr 29.

12.

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.

Lung Cancer. 2011 Oct;74(1):55-60. doi: 10.1016/j.lungcan.2011.02.007. Epub 2011 Mar 12.

PMID:
21397972
13.

Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.

Demir M, Kaya H, Taylan M, Ekinci A, Yılmaz S, Teke F, Sezgi C, Tanrikulu AC, Meteroglu F, Senyigit A.

Lung. 2016 Jun;194(3):409-17. doi: 10.1007/s00408-016-9868-1. Epub 2016 Mar 31.

PMID:
27032653
14.

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.

Burt BM, Lee HS, Lenge De Rosen V, Hamaji M, Groth SS, Wheeler TM, Sugarbaker DJ.

Ann Thorac Surg. 2017 Nov;104(5):1679-1687. doi: 10.1016/j.athoracsur.2017.06.042. Epub 2017 Sep 28.

PMID:
28964420
15.

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.

Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ.

BMJ Open. 2014 Feb 24;4(2):e004145. doi: 10.1136/bmjopen-2013-004145.

16.

Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.

Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.

J Thorac Oncol. 2011 Sep;6(9):1587-93. doi: 10.1097/JTO.0b013e31821e1c08.

17.

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.

Lung Cancer. 2013 Dec;82(3):491-8. doi: 10.1016/j.lungcan.2013.09.016. Epub 2013 Oct 9.

PMID:
24161718
18.

The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.

Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, Bosquée L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.

Chest. 2012 Feb;141(2):477-484. doi: 10.1378/chest.11-0129. Epub 2011 Jul 7.

PMID:
21737491
19.

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.

Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P.

Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60. Epub 2006 Feb 2.

PMID:
16456138
20.

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK.

Clin Cancer Res. 2011 Mar 1;17(5):1181-9. doi: 10.1158/1078-0432.CCR-10-1929. Epub 2010 Dec 21.

Supplemental Content

Support Center